Immunomedics Inc. Hits New 52-Week High at $7.35 (IMMU)
Shares of Immunomedics (NASDAQ:IMMU) hit a new 52-week high on Wednesday, AR Network reports. The company traded as high as $7.35 and last traded at $7.20, with a volume of 2,680,811 shares trading hands. The stock had previously closed at $6.81.
IMMU has been the subject of a number of recent research reports. Analysts at Oppenheimer raised their price target on shares of Immunomedics (NASDAQ:IMMU) from $6.00 to $8.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Analysts at R. F. Lafferty initiated coverage on shares of Immunomedics (NASDAQ:IMMU) in a research note to investors on Tuesday, September 10th. They set a “buy” rating and a $8.00 price target on the stock.
Immunomedics has a one year low of $2.11 and a one year high of $6.91. The stock’s 50-day moving average is $5.88 and its 200-day moving average is $4.3. The company’s market cap is $590.5 million.
Immunomedics (NASDAQ:IMMU) last announced its earnings results on Thursday, August 22nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $0.81 million. Analysts expect that Immunomedics will post $-0.25 EPS for the current fiscal year.
Develops antibody-based medical products used to detect, diagnose and treat cancer. The Company is particularly focused on developing products in the following areas: in-vitro diagnostic tests for the detection of cancer and certain autoimmune diseases; in-vivo imaging products for the early detection and diagnosis of cancer using a method called radioimmunodetection; in-vivo therapeutic products used in the targeted delivery of therapeutic doses of radioisotopes colorectal and gastrointestinal cancer tissues.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.